Hepatitis C News and Research

Latest Hepatitis C News and Research

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in people with active rheumatoid arthritis (RA) taking methotrexate

19 Oct 2013

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir AB (OMX:MVIR-B) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients.

19 Oct 2013

HBV-infected men more likely to develop liver cancer

A team of researchers has identified a novel mutation in the hepatitis B virus (HBV) in Korea that appears only in men and could help explain why HBV-infected men are roughly five times more likely than HBV-infected women to develop liver cancer.

18 Oct 2013

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma tumors - the most common form of liver cancer. The researchers found ways to identify and isolate the HCC progenitor cells long before actual tumors were apparent.

11 Oct 2013

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association.

11 Oct 2013

Patients who received care at multiple HIV clinics have higher HIV viral loads

Patients who received care at multiple HIV clinics—as opposed to only one— were less likely to take their medication and had higher HIV viral loads, a new study published in the journal AIDS and Behavior of almost 13,000 HIV patients in Philadelphia from Penn Medicine found.

10 Oct 2013

Receiving care at several HIV clinics may increase medication errors

Patients who received care at multiple HIV clinics-as opposed to only one- were less likely to take their medication and had higher HIV viral loads, a new study published in the journal AIDS and Behavior of almost 13,000 HIV patients in Philadelphia from Penn Medicine found.

10 Oct 2013

Research on flaviviruses could help in developing effective therapies for persistent infections

We generally do not devote much time to worrying about the problems faced by viruses, although understanding them may provide clues on how to combat diseases.

9 Oct 2013

Researchers recently launched Collaborative Hepatitis Network in Africa

Although it does not receive as much attention as AIDS, hepatitis has long been one of Africa's most serious health problems.

9 Oct 2013

Healthcare providers report unaccompanied teens may not receive required vaccines

Healthcare providers report that older teens often go to the doctor without a parent or guardian, a new survey in the Journal of Adolescent Health reveals—and those teens may not get necessary vaccinations because there's no parent or guardian present to give consent.

9 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

A major study conducted at the Sahlgrenska Academy has now disproved theories of a viral cause for breast cancer and the brain tumour, glioblastoma. The study, which was based on over seven billion DNA sequences and which is published in Nature Communications, found no genetic traces of viruses in these forms of cancer.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...

8 Oct 2013

Vaccination campaign led HBV to more than double rate of "breakout" mutations

A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.

8 Oct 2013

New injection device delivers optimum treatment dose to hepatitis C patients

A new injection device, ViraferonPeg Clearclick, has launched in the UK today for hepatitis C patients to accurately titrate and self-administer their weekly dose of ViraferonPeg (peginterferon alfa-2b).

5 Oct 2013

Saint Luke's liver transplantation program receives CMS certification

The liver transplantation program at Saint Luke's Hospital of Kansas City has received certification by the Centers for Medicare and Medicaid. The certification is an important step in enhancing the hospital's ability to care for Medicare-covered patients suffering from end-stage liver disease, and attract other insurers who base their coverage on the CMS certification.

2 Oct 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

HBV-infected men more likely to develop liver cancer

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

Patients who received care at multiple HIV clinics have higher HIV viral loads

Receiving care at several HIV clinics may increase medication errors

Research on flaviviruses could help in developing effective therapies for persistent infections

Researchers recently launched Collaborative Hepatitis Network in Africa

Healthcare providers report unaccompanied teens may not receive required vaccines

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

Vaccination campaign led HBV to more than double rate of "breakout" mutations

New injection device delivers optimum treatment dose to hepatitis C patients

Saint Luke's liver transplantation program receives CMS certification

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in